Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 4 Waldenstrom Macroglobulinemia 1 Recurrence 1 Lymphoma, T-Cell, Peripheral 1 Immunoglobulin Light-chain Amyloidosis 1

Interventions

Cyclophosphamide 26 fludarabine 18 Dexamethasone 17 pembrolizumab 12 Rituximab 11 Etoposide 10 venetoclax 9 pomalidomide 9 Gemcitabine 9 fludarabine phosphate 7 daratumumab 7 Lenalidomide 7 Bortezomib 7 carfilzomib 6 obinutuzumab 5 glofitamab 5 Vincristine 5 Temozolomide 5 Prednisone 5 Nivolumab 5 Immunotherapy, Adoptive 5 Cisplatin 5 Calcium Dobesilate 5 selinexor 4 cemiplimab 4 Doxorubicin 4 Cytarabine 4 Carboplatin 4 zanubrutinib 3 ruxolitinib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × ixazomib × 90 days × Clear all

NCT02343042 2026-05-04

STOMP

Karyopharm Therapeutics Inc

Phase 1/2 Active not recruiting

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡